德康医疗（DXCM）今日夜盘股价大涨7.28%，引发市场广泛关注。
消息面上，公司盘后公布的季度业绩全面超出市场预期，并上调了全年营收指引，成为推动股价上涨的主要催化剂。得益于连续血糖监测仪（CGM）的强劲需求，德康医疗第二季度营收达到13.1亿美元，同比增长13%，高于分析师预期的12.9亿美元；调整后每股收益为70美分，同样优于市场预期的61美分。公司还预计全年营收将在51.8亿美元至52.5亿美元之间，较此前指引有所上调，分析师平均预期为52.2亿美元。
随着糖尿病护理意识提升、保险覆盖范围扩大，以及消费者对无创监测技术的偏好增加，连续血糖监测仪市场需求持续旺盛，支撑了德康医疗等龙头厂商的业绩表现与市场信心。此外，公司G7系统近期获得加拿大卫生部授权，德国市场推出Flex系统拓展2型糖尿病覆盖，多项利好因素叠加，进一步提振了投资者情绪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.